Analysis of Bifidobacterium animalis subsp. lactis BB-12 ® and Lactobacillus rhamnosus GG on underweight and malabsorption in premature infants
- PMID: 38422245
- PMCID: PMC10890203
- DOI: 10.1590/1806-9282.20230636
Analysis of Bifidobacterium animalis subsp. lactis BB-12 ® and Lactobacillus rhamnosus GG on underweight and malabsorption in premature infants
Abstract
Objective: This study aimed to explore and analyze the therapeutic effect of the combination of Bifidobacterium animalis subsp. lactis BB-12® and Lactobacillus rhamnosus GG on underweight and malabsorption in premature infants.
Methods: This is a retrospective study. The clinical data of 68 premature infants admitted to Beijing United Family Hospital (Private Secondary Comprehensive Hospital, Chaoyang District, Beijing, China) from January 2016 to January 2022 were analyzed retrospectively. Preterm infants less than 37 weeks of gestational age admitted to the neonatal intensive care unit were included in the study. Patients with intestinal malformations, necrotizing enterocolitis, etc., who require long-term fasting were excluded. A telephone follow-up was performed 3-6 months after discharge. They were classified as treatment groups A and B according to the treatment plan. The treatment group A included parenteral nutrition, enteral nutrition, etc. In treatment group B, based on treatment group A, the premature infants were treated with Bifidobacterium animalis subsp. lactis BB-12® and Lactobacillus rhamnosus GG. The time to regain birthweight and the weight on day 30 were compared between the two groups, as was the duration of transition from parenteral nutrition to total enteral nutrition.
Results: The time of weight regain birthweight in group B was shorter than that in group A (t=-2.560; t=-4.287; p<0.05). The increase of weight on day 30 in group B was significantly higher than that in group A (t=2.591; t=2.651; p<0.05). The time from parenteral nutrition to total enteral nutrition in group B was shorter than that in group A (z=-2.145; z=-2.236; p<0.05).
Conclusion: In the treatment of premature infants, the combination of Bifidobacterium animalis subsp. lactis BB-12® and Lactobacillus rhamnosus GG can have a better therapeutic effect on the underweight and malabsorption of premature infants, and this treatment method can be popularized in clinics.
Conflict of interest statement
Similar articles
-
Assessment of stress tolerance acquisition in the heat-tolerant derivative strains of Bifidobacterium animalis subsp. lactis BB-12 and Lactobacillus rhamnosus GG.J Appl Microbiol. 2014 Jul;117(1):239-48. doi: 10.1111/jam.12520. Epub 2014 Apr 29. J Appl Microbiol. 2014. PMID: 24724909
-
The effect of early probiotic exposure on the preterm infant gut microbiome development.Gut Microbes. 2021 Jan-Dec;13(1):1951113. doi: 10.1080/19490976.2021.1951113. Gut Microbes. 2021. PMID: 34264803 Free PMC article.
-
Restitution of gut microbiota in Ugandan children administered with probiotics (Lactobacillus rhamnosus GG and Bifidobacterium animalis subsp. lactis BB-12) during treatment for severe acute malnutrition.Gut Microbes. 2020 Jul 3;11(4):855-867. doi: 10.1080/19490976.2020.1712982. Epub 2020 Jan 20. Gut Microbes. 2020. PMID: 31959047 Free PMC article. Clinical Trial.
-
Health benefits of Lactobacillus rhamnosus GG and Bifidobacterium animalis subspecies lactis BB-12 in children.Postgrad Med. 2020 Jun;132(5):441-451. doi: 10.1080/00325481.2020.1731214. Epub 2020 Feb 26. Postgrad Med. 2020. PMID: 32059116 Review.
-
Probiotics to prevent necrotizing enterocolitis in very low birth weight infants: A network meta-analysis.Front Pediatr. 2023 Mar 6;11:1095368. doi: 10.3389/fped.2023.1095368. eCollection 2023. Front Pediatr. 2023. PMID: 36950176 Free PMC article. Review.
References
MeSH terms
LinkOut - more resources
Full Text Sources